Arvinas Inc. (ARVN) reported its earnings for the fourth quarter of 2024, revealing a smaller-than-expected loss per share ...
23h
Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial isanticipated in 1Q25 –– Presented Phase 1b data from the TACTIVE-U ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback